Global Mental Disorder Cases Reach 1.17 Billion as Youth Diagnoses and Treatment Gaps Widen

A systematic analysis of global disease burden estimates that 1.17 billion people worldwide were living with a mental disorder in 2023 (95% CI 1.06–1.31 billion), equivalent to 14,210.7 cases per 100,000 people — a 95.5% increase since 1990, according to a Lancet study covering 375 diseases and injuries across 21 regions and 204 countries and territories. All 12 mental disorders examined showed increases over the period, with particularly steep rises in anxiety disorders (搜索)搜索该疾病, major depressive disorder (搜索)搜索该疾病 (MDD), dysthymia, anorexia nervosa (搜索)搜索该疾病, bulimia nervosa (搜索)搜索该疾病, schizophrenia (搜索)搜索该疾病, and conduct disorder (搜索)搜索该疾病.

Mental disorders accounted for 6.1% of all disability-adjusted life-years (DALYs) in 2023, making them the fifth leading cause of years of full health lost to disability or illness, up from 12th place in 1990. When restricted to non-communicable diseases, mental disorders ranked third, behind cardiovascular diseases and neoplasms. Every country reported increases between 1990 and 2023.

Anxiety and Depression Dominate Burden, Especially in Youth

Anxiety was the leading cause of DALYs among mental disorders globally, ranking fifth overall, followed by MDD (15th) and schizophrenia (搜索)搜索该疾病 (41st). Among adolescents aged 15–19, anxiety was the largest cause of DALYs, followed by MDD, conduct disorder (搜索)搜索该疾病, and autism spectrum disorders. These impacts were greater in females than males among the young, driven by higher rates of anxiety disorders (搜索)搜索该疾病 and MDD in females, whereas conduct disorder and autism spectrum disorders were more prevalent in males.

The authors attribute part of the increase to declining mortality from communicable, maternal, nutritional, and neonatal diseases that allow people to live longer, alongside persistent treatment gaps.

Treatment Gap Persists Despite Rising Burden

Citing a previous study, the authors report that only 9.1% of individuals with MDD received "medically adequate treatment" in 2021 — defined as either one month of medication plus four medical visits, or eight sessions of psychotherapy. Treatment rates were 10.2% for females with MDD and 7.2% for males. Only seven countries reached a treatment rate of 30% (Australia, Belgium, Canada, Germany, the Netherlands, South Korea, and Sweden), while 90 countries remained below 5%. Sub-Saharan Africa stood at 2%, implying a 98% treatment gap for MDD — of every 100 people with major depression in the region in 2021, two received medically adequate treatment.

The authors call for stronger mental health surveillance, particularly in low- and middle-income countries, and for inclusive policies emphasizing early treatment and prevention tailored to sex and age differences globally.

Youth Diagnoses Show Marked Regional Divergence

A separate review in Nature examining the global rise in youth mental health diagnoses documents substantial heterogeneity across disorders and regions. Depression in adolescence represents one of the most pronounced increases in genuine psychiatric morbidity in high-income regions: 12-month MDD prevalence in high-SDI regions has nearly doubled over two decades, with US adolescent rates rising from 8.1% in 2009 to 15.8% in 2019. A meta-analysis estimated that approximately one in five children under 18 experiences MDD or clinically significant depressive symptoms.

Anxiety prevalence also climbed across developmental stages, particularly among females. In the USA, anxiety in children and adolescents rose from 7.1% to 9.2% between 2016 and 2020, while prevalence among young adults increased from 8% to 14.7% between 2008 and 2018. Generalized anxiety among adolescent females increased from 15.5% in 2013 to 19.7% in 2019, with a slight decline in males over the same period; high-level social anxiety symptoms doubled among female Finnish adolescents between 2013 and 2021.

Suicide, described in the review as one of the most objective indicators of genuine deterioration in youth mental health, has risen sharply in several high-income countries. In the USA, suicide rates for 10–24-year-olds increased by 62% from 2007 to 2021, from 6.8 to 11.0 deaths per 100,000. Australia recorded a 52% increase among those aged 15–17 (from 6 to 9.1 per 100,000) and 46% among those aged 18–24 (from 10.3 to 15 per 100,000) between 2009 and 2021. Taiwan has reported approximately 12% annual increases among ages 10–24 since 2014, and China annual increases of 18% and 15% in the 10–14 and 15–19 age groups, respectively, between 2017 and 2021. Recent data from the USA, Australia, and Taiwan indicate a disproportionate rise in female youth suicide.

Diagnostic Expansion Versus True Morbidity

The review distinguishes genuine increases in morbidity from diagnostic artifacts. Autism spectrum disorder (搜索)搜索该疾病 prevalence shows marked global variability — from 476 per 100,000 in France to 3,130 per 100,000 in Iceland among children aged 7–9 — while the GBD 2021 update indicates a relatively stable global age-standardized prevalence of 788 per 100,000. Localized increases in high-SDI countries are largely attributed to improved diagnostic practices and expanded screening rather than a true rise in underlying pathology.

Similarly, US ADHD prevalence increased from 6–8% in 2000 to 11% by 2020, partly reflecting DSM-5 revisions that extended the age-of-onset criterion to 12 years and lowered adult diagnostic thresholds, while global age-standardized estimates show declines of up to 8.75%. DSM-5 changes also increased parent-reported OCD prevalence in youths by approximately 10% compared with DSM-IV after removal of the requirements for marked anxiety or distress and for recognition of symptoms as excessive or unreasonable.

For depression, the review notes that earlier clinical presentation may partly reflect enhanced mental health literacy and prevalence inflation rather than a purely biological shift, but states these factors alone cannot account for the magnitude of observed increases. Declining trends in lower-income regions likely reflect under-detection, stigma, and limited access to services.

Substance Use and Psychosis Risk Shift With Legalization

The review highlights cannabis legalization as a measurable driver of psychosis burden. A large population-based cohort study in Canada found that the proportion of schizophrenia (搜索)搜索该疾病 cases attributable to cannabis use disorder (搜索)搜索该疾病 nearly tripled from 3.7% pre-legalization to 10.3% following nonmedical cannabis legalization, with the highest attributable risk (18.9%) among males aged 19 to 24. In the USA, marijuana legalization has been associated with higher suicide rates among youths aged 12–25, particularly females, after adjustment for multiple covariates. By 2020, more than 1,000 novel psychoactive substances had been identified, complicating surveillance and toxicological screening.

Environmental Drivers Converge on the Developing Brain

The review identifies interconnected mechanisms linking contemporary environments to youth psychopathology. Longitudinal cohorts including the Adolescent Brain Cognitive Development (ABCD) study show that greater baseline screen time prospectively predicts increases in depressive, conduct, somatic, and ADHD symptoms over two-year follow-up, partly explained by the displacement of protective behaviors such as sleep and physical activity. A randomized controlled trial found that a two-week, family-based reduction in leisure screen time improved youths' emotional symptoms and peer interactions.

Cyberbullying now affects approximately 15% of youths globally. Victims face a 2.8-fold increased risk of depression, rising to 3.2-fold among those in bully-victim roles, with cyberbullying victimization uniquely linked to suicide attempts and acute emotional distress, particularly among female adolescents.

Sleep and circadian disruption are positioned as neurobiological targets: insomnia affects 30–40% of youths, and an eveningness chronotype is present in approximately 20%. ABCD longitudinal data identify sleep disturbance as one of the strongest predictors of subsequent adolescent mental health risk, and meta-analytic evidence shows that improving sleep confers cross-diagnostic benefits for depression, anxiety, and rumination.

Physical activity data show that 81% of adolescents worldwide fail to meet the recommended 60 minutes of daily moderate-to-vigorous activity. Higher childhood cardiorespiratory and muscular fitness predicts reduced risk of subsequently developing ADHD, depression, and anxiety.

A Stepped Framework for Prevention and Care

The review proposes a three-tier intervention model: universal prevention for all youths, selective interventions for high-risk subgroups, and indicated care for established disorders. Universal strategies include digital literacy curricula, family screen-free times and zones to protect sleep, mandatory daily physical education, and school culture reform to reduce assessment stakes. A meta-analysis of 570,000 students found that social-emotional learning interventions improved social functioning, school climate, and long-term academic outcomes, though with substantial heterogeneity across contexts.

Selective interventions emphasize systematic sleep screening, structured physical activity programs for vulnerable youths, and proactive monitoring of those at elevated risk of cyberbullying, including youths with disabilities, neurodevelopmental conditions, LGBTQ identities, and social anxiety. Indicated care prioritizes cognitive behavioral therapy (搜索)搜索该药品 for internalizing disorders, dialectical behavior therapy (搜索)搜索该药品 for chronic suicidality or emotional dysregulation, individualized safety plans with lethal means restriction, and structured return-to-learn protocols following psychiatric hospitalization.

The Lancet authors similarly emphasize inclusive policies focused on early treatment and prevention, tailored to sex and age differences, alongside stronger surveillance in low- and middle-income countries — a call echoed by the review's conclusion that addressing rising youth psychiatric morbidity requires a paradigm shift from reactive, diagnosis-centered care toward proactive risk mitigation and strengthening of protective factors.